CM336 with Isa-VR for newly diagnosed plasma cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination treatment for people who have just been diagnosed with primary plasma cell leukemia. The treatment includes a study drug called CM336 along with other cancer-fighting medicines. It aims to see if this combination helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have newly diagnosed primary plasma cell leukemia and have had at most 1 previous anti-myeloma treatment cycle.
- Your disease is measurable by certain blood or urine tests (like M-protein or free light chains).
- Your liver, kidney, and blood counts are within levels that the study considers safe.
- You are able and willing to take blood thinners to prevent clots.
- You agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells boosted with a protein called IL-15) for people with multiple myeloma or plasma cell leukemia that has not responded to standard treatments or has come back. The goal is to see if these enhanced cells can better fight the cancer.
This trial tests a new CAR-T cell therapy (IASO104) for people whose multiple myeloma has come back or not responded to other treatments. It aims to see if this therapy can help reduce or eliminate the cancer.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
This trial tests a combination of two drugs, CM336 and isatuximab, for people newly diagnosed with multiple myeloma who also have kidney problems caused by the disease. The goal is to see if this combination can help control the myeloma while also improving kidney function.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
Hear when a new Plasma Cell Leukemia (PCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.